AlphaCore Capital LLC Increases Stock Position in AstraZeneca PLC $AZN

AlphaCore Capital LLC boosted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 77.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,230 shares of the company’s stock after acquiring an additional 6,206 shares during the quarter. AlphaCore Capital LLC’s holdings in AstraZeneca were worth $1,092,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of AZN. NewSquare Capital LLC lifted its holdings in shares of AstraZeneca by 149.3% during the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after purchasing an additional 218 shares in the last quarter. Rakuten Investment Management Inc. purchased a new position in AstraZeneca in the 3rd quarter worth about $31,000. FSA Wealth Management LLC raised its position in AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock worth $33,000 after buying an additional 376 shares during the last quarter. VSM Wealth Advisory LLC bought a new position in AstraZeneca during the 2nd quarter valued at about $33,000. Finally, E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of AstraZeneca by 144.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock valued at $36,000 after acquiring an additional 275 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Up 2.3%

AZN stock opened at $208.72 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. AstraZeneca PLC has a 1-year low of $122.48 and a 1-year high of $212.71. The business has a 50 day simple moving average of $135.91 and a two-hundred day simple moving average of $102.01. The company has a market capitalization of $323.71 billion, a price-to-earnings ratio of 69.34, a PEG ratio of 1.59 and a beta of 0.34.

AstraZeneca Dividend Announcement

The business also recently declared a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be issued a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date is Friday, February 20th. AstraZeneca’s payout ratio is currently 74.83%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of AstraZeneca in a report on Friday, February 6th. Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a research note on Wednesday, December 3rd. Barclays restated an “overweight” rating on shares of AstraZeneca in a research note on Tuesday, January 6th. Wall Street Zen cut AstraZeneca from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 17th. Finally, Citigroup initiated coverage on AstraZeneca in a research report on Tuesday, January 27th. They issued a “buy” rating on the stock. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.